Florida-based company Morphogenesis developed a canine lymphoma cell-processing treatment, a process in which tumor cells become a target for the immune system by being labeled with a bacterial protein. Researchers at Morphogenesis are now developing a vaccine from stock cells instead of using a patient's own tumor cells, which could allow the treatment to become widely available.

Full Story:

Related Summaries